Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Everest Medicines Launches Etrasimod in China – Next-Gen S1P Modulator Hits Market for Ulcerative Colitis

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Policy / Regulatory

China’s Health Authorities Release Third List of 41 Drugs for Recommended Generic Development

Fineline Cube Oct 31, 2023

The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA),...

Company Drug

CSPC Pharmaceutical Group Gains NMPA Approval for Bivalent COVID-19 mRNA Vaccine Study

Fineline Cube Oct 31, 2023

CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent pharmaceutical company based in China, has announced...

Company Drug

GenFleet Therapeutics’ SLS009 Receives FDA Fast-Track Status for PTCL Treatment

Fineline Cube Oct 31, 2023

Shanghai-based biotech GenFleet Therapeutics has announced that its investigational drug SLS009 (GFH009) has received fast-track...

Company Drug

CStone Pharmaceuticals Receives NMPA Approval for Sugemalimab in R/R ENKTL

Fineline Cube Oct 31, 2023

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received a...

Company Drug

Simcere Pharmaceutical Group Secures Full Approval for Cosela in China

Fineline Cube Oct 31, 2023

Simcere Pharmaceutical Group (HKG: 2096), a leading pharmaceutical company based in China, has announced that...

Company Drug

Novartis Announces Positive Interim Results for Atrasentan in IgA Nephropathy Phase III Study

Fineline Cube Oct 31, 2023

Novartis (NYSE: NVS), a global healthcare company, has released interim results from an ongoing Phase...

Company Deals

BMS and Karyopharm Partner to Evaluate Mezigdomide and Xpovio in Relapsed/Refractory Multiple Myeloma

Fineline Cube Oct 31, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has entered into a collaboration and supply agreement with...

Company Legal / IP

Novartis Seeks Access to Takeda’s Business Records Over Confidentiality Concerns

Fineline Cube Oct 30, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) filed a complaint with a US court last week,...

Company Drug

Roche’s Vabysmo Receives FDA Approval for Macular Edema Treatment Following RVO

Fineline Cube Oct 30, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) announced last week that it has received an indication...

Company

AbbVie’s Q3 2023 Report Shows 6.0% YOY Decline in Net Revenues

Fineline Cube Oct 30, 2023

AbbVie (NYSE: ABBV) released its Q3 2023 financial report last week, revealing a 6.0% year-on-year...

Company

Dr. Reddy’s Laboratories Reports 9% YOY Revenue Growth in Q2 2024 Fiscal Year

Fineline Cube Oct 30, 2023

India-based generics giant Dr. Reddy’s Laboratories Ltd (NYSE: RDY) has released its financial report for...

Company Medical Device

Jenscare Scientific’s Ken Valve Enters NMPA Priority Review for Aortic Valve System

Fineline Cube Oct 30, 2023

Jenscare Scientific Co., Ltd (HKG: 9877), a leading structural heart disease device manufacturer based in...

Company Drug

Alphamab Oncology and 3D Medicines Gain FDA Approval for Envafolimab Phase III Trial

Fineline Cube Oct 30, 2023

Partners Alphamab Oncology (HKG: 9966) and 3D Medicines (HKG: 1244) have announced that they have...

Company Drug

China Grand Pharma’s Lava Liquid Embolic Agent Officially Commercialized in the US

Fineline Cube Oct 30, 2023

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the official commercialization...

Company

Mindray Bio-Medical Electronics Posts Strong Q1-Q3 2023 Financial Results

Fineline Cube Oct 30, 2023

Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has revealed a robust financial performance for...

Company Drug

Fosun Pharma Gains NMPA Approval for Clinical Trials of HLX42 and HLX43 ADCs

Fineline Cube Oct 30, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced that it has received approval...

Company Drug

Innovent Biologics’ Mazdutide Shows Promising Weight Loss Results in Phase II Trial

Fineline Cube Oct 30, 2023

China-based Innovent Biologics Inc., (HKG: 1801) has revealed compelling Phase II data for its weight...

Company

Sanofi SA Reports Q3 2023 Financials with Focus on R&D and Dupixent Growth

Fineline Cube Oct 30, 2023

French pharmaceutical giant Sanofi SA (NASDAQ: SNY) released its Q3 2023 financial results, reporting a...

Company Drug

Junshi Biosciences’ PD-1 Inhibitor Loqtorzi Approved by FDA for Nasopharyngeal Carcinoma

Fineline Cube Oct 30, 2023

China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the US...

Company Drug

TG ImmunoPharma’s Bispecific Antibody TGI-6 Approved for Phase I Clinical Study by NMPA

Fineline Cube Oct 30, 2023

China-based TG ImmunoPharma Co., Ltd has announced that it has received approval from the National...

Posts pagination

1 … 418 419 420 … 632

Recent updates

  • GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value
  • FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market
  • Everest Medicines Launches Etrasimod in China – Next-Gen S1P Modulator Hits Market for Ulcerative Colitis
  • FDA Advances Section 804 Drug Importation Program – States Meet Agency on Canadian Prescription Import Pathway
  • Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Company Drug

Everest Medicines Launches Etrasimod in China – Next-Gen S1P Modulator Hits Market for Ulcerative Colitis

Policy / Regulatory

FDA Advances Section 804 Drug Importation Program – States Meet Agency on Canadian Prescription Import Pathway

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.